Automating stapled peptide synthesis: overcoming DMF poisoning
Small molecules and synthetic therapeutics
Fully automating synthesis and secondary chemistry is always desirable, unless it comes at a cost of yield or purity. Read more for ...
Small molecules and synthetic therapeutics
Fully automating synthesis and secondary chemistry is always desirable, unless it comes at a cost of yield or purity. Read more for ...
Small molecules and synthetic therapeutics
Particle size and pore size can both impact resolution, but especially when using reversed phase flash chromatography. Read more to see ...
Small molecules and synthetic therapeutics
The articles contains an interview to Richard E. Johnsson, Ph.D., Head of Peptide Chemistry at Red Glead Discovery, Lund, Sweden, who ...
Small molecules and synthetic therapeutics
The number of equivalents used in a synthesis can significantly impact the cost of a peptide synthesis. Read more to learn how few ...
Small molecules and synthetic therapeutics
Aspartimide rearrangements can negatively impact biological screening outcomes. Read more to learn methods to identify this side reaction ...
Small molecules and synthetic therapeutics
Aspartimide rearrangements are one of the most ubiquitous side reactions encountered during solid phase synthesis. Read more to learn how ...
Small molecules and synthetic therapeutics
Choosing a stationary phase seems relatively straightforward, almost automatic even. See how selectivity differences could impact your ...
Small molecules and synthetic therapeutics
Sometimes closely eluting impurities are difficult to resolve by simply changing the gradient. Learn how ion pairing agents can help.
Small molecules and synthetic therapeutics
Mass directed purification simplifies purification efforts. Read more how it can be used to reduce your purification time with flash ...
Small molecules and synthetic therapeutics
In this blog, Beth highlights the role of of scavengers for peptides containing cysteine residues.